Street-corner oratory may seem like a dying art, but if there's one place you can still find people literally up on their soapboxes, spewing views on religion, politics, or ethics, it's New York City. And, if there's one time I religiously follow the advice of my native New Yorker father ("Look down while you're walking and don't make eye contact with people you pass"), it's when I see these soapbox stars and the crowds surrounding them.
Street-corner oratory may seem like a dying art, but if there's one place you can still find people literally up on their soapboxes, spewing views on religion, politics, or ethics, it's New York City. And, if there's one time I religiously follow the advice of my native New Yorker father ("Look down while you're walking and don't make eye contact with people you pass"), it's when I see these soapbox stars and the crowds surrounding them.
Kaylynn Chiarello-Ebner
No matter how passionately they make their cases, I never stop to listen to their views on global warming or the current presidential administration. Really, what's the value of taking the time to listen to a stranger's random thoughts and rants?
I'll tell you. Though not everyone has access to a street corner and a crowd, Web logs (or "blogs") are readily available. Bloggers electronically publish comments for all to read on every issue imaginable, including the pharmaceutical industry. Be they conversational or academic, it may be useful to tune in to the developing pharma dialogue.
A recent San Francisco Business Chronicle article claimed the pharmaceutical industry is "not hip" to blogging. The reason? Drug makers are wary of reading a blogger's description of an adverse event that might start the clock for reporting the problem to FDA.
Though it would be helpful to know how FDA would treat these unwelcome discoveries, patient blogs could be useful for culling together unfettered feedback on products or quickly spreading the word about recalls. On the manufacturing side, we could use industry-hosted blogs to exchange views about new FDA guidances, provide advice about cost-cutting manufacturing strategies, or debate the best tableting techniques.
Yes, most blogs are neither edited nor fact checked, and information must be taken with a grain of salt. But, an open dialogue could be a good resource, provided industry folks are willing to lend a cautious ear and a voice. Now and then, I'll be sure to pause on the virtual corner to take in some soapbox speechifying.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.